Abstract
Stenting for the prevention of atherosclerosis related ischemic strokes is a recent option in the therapeutic armamentarium. For extracranial carotid artery stenosis, stenting has proven its benefit in patients defined as “high-risk” for surgery, but beyond this specific population, surgery remains the gold standard. Based on recent prospective randomized trials, carotid endarterectomy (CEA) and carotid artery stenting (CAS) seem to share equivalent peri-procedural stroke risks, but the significantly higher rates of local nerve injury and myocardial infarction related to the surgical approach should favor the endovascular intervention in the future. In other locations, such as extracranial vertebral artery or intracranial stenoses, the current practice of care is not defined and the benefit of stenting is under investigation. However, in patients with symptomatic lesions despite appropriate antithrombotic therapy, stenting is considered to have a better benefit/risk profile in comparison to intracranial bypass surgery. In-stent restenosis (ISR), a major concern after stenting in coronary arteries, is an infrequent event following cervical internal carotid stenting but is relatively common and may worsen outcomes following treatment of extracranial vertebral and intracranial arterial stenoses. Drug eluting stents have proven their efficacy to control ISR and have changed dramatically the landscape of interventional cardiology, for this purpose their evaluation is now starting in the cerebral vasculature. The field of endovascular interventions is rapidly evolving and the development of devices dedicated to the cerebral vasculature is without any doubt going to extend the spectrum of treatable lesions.
Keywords: Extracranial and intracranial arteries-Stenting-ISR-DES-.
Current Drug Targets
Title: Stenting and Prevention of Ischemic Stroke
Volume: 8 Issue: 7
Author(s): Mikael Mazighi and Alex Abou-Chebl
Affiliation:
Keywords: Extracranial and intracranial arteries-Stenting-ISR-DES-.
Abstract: Stenting for the prevention of atherosclerosis related ischemic strokes is a recent option in the therapeutic armamentarium. For extracranial carotid artery stenosis, stenting has proven its benefit in patients defined as “high-risk” for surgery, but beyond this specific population, surgery remains the gold standard. Based on recent prospective randomized trials, carotid endarterectomy (CEA) and carotid artery stenting (CAS) seem to share equivalent peri-procedural stroke risks, but the significantly higher rates of local nerve injury and myocardial infarction related to the surgical approach should favor the endovascular intervention in the future. In other locations, such as extracranial vertebral artery or intracranial stenoses, the current practice of care is not defined and the benefit of stenting is under investigation. However, in patients with symptomatic lesions despite appropriate antithrombotic therapy, stenting is considered to have a better benefit/risk profile in comparison to intracranial bypass surgery. In-stent restenosis (ISR), a major concern after stenting in coronary arteries, is an infrequent event following cervical internal carotid stenting but is relatively common and may worsen outcomes following treatment of extracranial vertebral and intracranial arterial stenoses. Drug eluting stents have proven their efficacy to control ISR and have changed dramatically the landscape of interventional cardiology, for this purpose their evaluation is now starting in the cerebral vasculature. The field of endovascular interventions is rapidly evolving and the development of devices dedicated to the cerebral vasculature is without any doubt going to extend the spectrum of treatable lesions.
Export Options
About this article
Cite this article as:
Mikael Mazighi and Alex Abou-Chebl , Stenting and Prevention of Ischemic Stroke, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077445
DOI https://dx.doi.org/10.2174/138945007781077445 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Automated Electrophysiology in Drug Discovery
Current Pharmaceutical Design Microcirculation and NO-CO Studies of a Natural Extracellular Hemoglobin Developed for an Oxygen Therapeutic Carrier
Current Drug Discovery Technologies Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology MicroRNAs as Candidate Drug Targets for Cardiovascular Diseases
Current Drug Targets Efficacy and Cardiovascular Safety of Metformin
Current Drug Safety Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Sex Differences in Clinical Outcomes of Patients with Stable Coronary Artery Disease after Percutaneous Coronary Intervention
Current Pharmaceutical Design Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Impact of Red Wine Consumption on Cardiovascular Health
Current Medicinal Chemistry Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Current Pharmaceutical Design Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Mineralocorticoid Receptor-Associated Hypertension and Target Organ Damage: Clinical Relevance for Resistant Hypertension in End Stage Renal Disease
Current Hypertension Reviews Editorial (Thematic Issue: The Long Way to a Successful Medical Therapy of Heart Failure with Beta-blockers in Children with Heart Disease)
Reviews on Recent Clinical Trials Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Post COVID-19
Infectious Disorders - Drug Targets Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Role of Ectonucleotidases in Synapse Formation During Brain Development: Physiological and Pathological Implications
Current Neuropharmacology Role of Heart Rate Reduction in the Management of Myocarditis
Current Pharmaceutical Design